Loading clinical trials...
Loading clinical trials...
The purpose of the study is to determine whether gene therapy is safe and effective for the treatment of severe childhood blindness caused by mutations in RPE65.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University College, London
Collaborators
NCT06789445 · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), and more
NCT04545736 · ABCA4 Retinopathy, Stargardt Disease, and more
NCT06305416 · Diabetic Macular Edema, Diabetic Retinopathy, and more
NCT05355415 · Retinal Degeneration, Age-Related Macular Degeneration, and more
NCT05921162 · Retinitis Pigmentosa, Retinal Disease, and more
Moorfields Eye Hospital NHS Foundation Trust
London
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions